Low concentrations of 17β‐estradiol exacerbate tamoxifen resistance in breast cancer treatment through membrane estrogen receptor‐mediated signaling pathways
- 25 November 2021
- journal article
- research article
- Published by Wiley in Environmental Toxicology
- Vol. 37 (3) , 514-526
Abstract
The present study aims to discover the influences of tamoxifen and 17β‐estradiol (E2) on tamoxifen‐resistant (TamR) patients in vitro. Herein, we established a stabilized TamR MCF‐7 cell line at 1 μM via gradient concentrations of tamoxifen cultivation. The expression changes of four ER subtypes (ERα66, ERβ, ERα36 and GPR30) were found to bring about tamoxifen resistance. Moreover, the generation of tamoxifen resistance involved in apoptosis escape via a reactive oxygen species‐regulated p53 signaling pathway. Interestingly, E2 at environmental concentrations (0.1–10 nM) could activate the expression of both ERα36 and GPR30, and then stimulate the phosphorylation of ERK1/2 and Akt, resulting in cell growth promotion. Cell migration and invasion promotion, apoptosis inhibition, and cell cycle G1‐S progression are involved in such proliferative effects. Conversely, the application of specific antagonists of ERα36 and GPR30 could restore tamoxifen's sensitivity as well as partially offset E2‐mediated proliferation. In short, overexpression of ERα36 and GPR30 not only ablate tamoxifen responsiveness but also could promote tumor progression of TamR breast cancer under estrogen conditions. These results provided novel insights into underlying mechanisms of tamoxifen resistance and the negative effects of steroid estrogens at environmental concentrations on TamR MCF‐7 cells, thus generating new thoughts for future management of ER‐positive breast cancer.Keywords
Funding Information
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
This publication has 48 references indexed in Scilit:
- A bi-faceted role of estrogen receptor β in breast cancerEndocrine-Related Cancer, 2013
- Membrane Estrogen Signaling Enhances Tumorigenesis and Metastatic Potential of Breast Cancer Cells via Estrogen Receptor-α36 (ERα36)Journal of Biological Chemistry, 2012
- Alternate Estrogen Receptors Promote Invasion of Inflammatory Breast Cancer Cells via Non-Genomic SignalingPLOS ONE, 2012
- Dynamic modelling of oestrogen signalling and cell fate in breast cancer cellsNature Reviews Cancer, 2011
- American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast CancerJournal of Clinical Oncology, 2010
- Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G2 cell-cycle arrestCell Death & Differentiation, 2010
- ER-α36, a Variant of ER-α, Promotes Tamoxifen Agonist Action in Endometrial Cancer Cells via the MAPK/ERK and PI3K/Akt PathwaysPLOS ONE, 2010
- Biological determinants of endocrine resistance in breast cancerNature Reviews Cancer, 2009
- Estrogen receptor‐alpha (ER‐α) suppresses expression of its variant ER‐α36FEBS Letters, 2009
- Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cellsCancer Chemotherapy and Pharmacology, 2007